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The Cancer Report from the World Health Organization states that in the year 2000 12% of all death cases worldwide were
caused by cancer. In the western world, the cancer death rates are often devastating, being at about 25%. This fact stresses the
urgency to ﬁnd eﬀective cures against malignant diseases. New approaches in the treatment of cancer focus on the development of
immunotherapies to ﬁght the disease. Besides other methods, the usage of tumor-speciﬁc RNA as part of vaccines is investigated
lately. RNA, administered alone or used for transfection of dendritic cells, shows several advantages as a vaccine including
feasibility, applicability, safeness, and eﬀectiveness when it comes to the generation of immune responses. This review concentrates
on results from in vitro experiments and recent trials using RNA vaccines to present an overview about this speciﬁc strategy.
1.Introduction
The diverse causes for cancer malignancies suggest that the
therapy of patients should be individualized to oﬀer an
eﬀective treatment for each person. Additionally, it is the
goal to intervene at the molecular level and manipulate
cells and ongoing processes to ﬁght disease. For quite some
time, the idea of using the own body’s immune system
for the treatment of cancer has been fascinating for its
apparent simplicity and probable eﬀectiveness. Due to this,
studies on the topic have been going on since the 1970s
[1–3]. At this time point ﬁrst ideas to employ RNA for
the generation of immune responses occurred and the
term immunotherapy emerged. So-called immune RNA was
extracted from lymphoid tissues of animals immunized with
tumor cells and injected into patients as adjuvants [1, 2].
As easy as the idea sounds, however, researchers have
been challenged with the complexity of the immune sys-
tem and the generation of speciﬁc and eﬀective immune
responses against desired targets. One issue, that makes
things both easier and more diﬃcult, is the origin of cancer,
which is altered self. It is easier, because tumor cells exhibit
distinct diﬀerences in comparison to nonaltered body cells.
Diﬃcult, because, for one, these cells are still self cells and,
second, they apply diverse mechanisms to evade recognition
by the immune system.
Nevertheless, diverse approaches have been taken to use
the diﬀerences between normal and tumor cells to teach
the immune system to recognize malignancies and eliminate
them. The goal in the generation of immunotherapeutic
vaccines is the induction and perpetuation of a tumor
speciﬁcimmuneresponse.Asaconsequencethebodyshould
be cleared from tumor cells, and additionally, the immune
systemshouldpreventtherecurrenceofthetumor.Therefore
it is necessary to generate a complete immune response
and to activate several leukocyte populations like antigen-
presenting cells, CD4+ and CD8+ T cells and B cells. This
will lead to the generation of memory cells, which have a
protective function after the clearance of tumor cells.
One focus of current research is the usage of messenger
RNA (mRNA) in diverse forms as a vaccine. In these
approaches mRNA encoding for tumor-associated antigens
or whole tumor cell RNA is applied to induce speciﬁc CTL
responses [4, 5]. Proceedings in experimental research and
recent trials are the topic of this review.
2. Tumor-AssociatedAntigens (TAAs)
An important step for vaccine development has been and
still is the identiﬁcation of tumor-associated antigens (TAAs)
[6]. As immune responses shall be induced, it is necessary2 Journal of Biomedicine and Biotechnology
to ﬁnd immunogenic molecules, which are upregulated or
bestexclusivelyexpressedincanceroustissuesbutnotoronly
lightly in healthy adult tissues.
Many TAAs are shared by tumor and normal tissues but
are indeed overexpressed in tumor cells. The use of these
broadly distributed antigens should be evaluated carefully, as
they induce tolerance due to the negative selection processes
during T cell development. If tolerance can be overcome,
the generation of immune responses against these antigens
might lead to the induction of autoimmune diseases. A
subgroup of shared TAAs are diﬀerentiation antigens. They
are not ubiquitously expressed, but speciﬁc for certain
tumors and the tissues these tumors derived from. An
example for diﬀerentiation antigens is Melan-A/MART-1
[7], which is almost solely expressed in melanoma cells and
melanocytes. Although the distribution of diﬀerentiation
antigens is restricted to certain tissues, the induction of
tolerance towards these antigens still poses a problem. And
again, it might be possible to create autoimmune eﬀects
when interfering with these TAAs.
A safer way to utilize the immune system would be the
induction of immune responses against antigens that are
uniquely expressed in tumor tissues. Two types of TAAs are
indeed speciﬁc for tumor cells. Cancer/testis (CT) antigens
[8] are expressed in several tumor tissues and in the germline
but cannot be found in somatic tissues. CT antigens are
not presented in the germline as MHC class I and class II
molecules get not expressed at site. This means that the anti-
gens will only be recognized in the tumor. In opposition to
shared tumor antigens, the generation of immune responses
will not lead to autoimmunity. An example for CT antigens
is NY-ESO-1 [9], which already has been used as a target
in immunotherapeutic approaches. Mutation antigens are
also exclusively expressed in tumor tissues. Cancer cells often
acquire several mutations, which lead to the translation of
altered proteins. If mutations occur in oncogenes or tumor
suppressor genes, this will induce the invasiveness of the
malign tumor. Mutation antigens are suited perfectly for
immunotherapy as these TAAs are not considered as self
by the immune system and no tolerance has been induced
towards them. Examples for mutation antigens are CDK4
[10], Kras [11], caspase8 [12], or TGF-β receptor [13–15].
Another group of tumor-speciﬁc antigens are TAAs of viral
origin. Several viruses, like HTLV-1, HIV, and EBV, induce
the generation of tumor cells. Particularly, the development
of non-Hodgkin lymphomas (NHL) and multiple myelomas
(MM) is associated with former viral infection. The altered
cells present viral antigens on their surface, which can be
the starting point for vaccine generation. In NHL and MM
disease, the idiotype of the immunoglobulin can be targeted
as well.
So far, depending on the type of disease, several useful
TAAs have been identiﬁed. For melanoma patients, MART-
1/Melan A [7], gp100 [16], and tyrosinase [17, 18]s e e mt o
be promising targets. The TAAs Survivin [19–21] and MUC-
1[ 22, 23] are expressed in a broad variety of epithelial and
haematological malignancies. CEA [24] is associated with
pancreatic, colorectal, or gastric cancer, while MAGE-A [6]
and NY-ESO-1 [9] are cancer testis antigens. Adipophilin
[25, 26], MMP-7 [27], RGS1 [28], and RGS5 [25, 29]
have recently been identiﬁed as renal cell carcinoma TAAs.
Examplesforleukemia-associatedantigensareWilms’tumor
protein (WT1) [30], proteinase 3 [31, 32], receptor for
hyaluronanacid-mediatedmotility(RHAMM)[33],andBax
inhibitor-1 [34].
3. Vaccine Delivery
Havingfoundspeciﬁcdiﬀerencesbetweentumorandhealthy
tissue, the next challenge is to teach the immune system to
perceive them. This is obviously done by administering the
TAAs to the body. The question is still: How is it done in the
best way?
Important issues to consider are the type of antigen,
which should be applied, and the way the antigens should
be delivered. When it comes to the type of antigen, diverse
approaches have been taken. Peptides from TAAs or whole
proteins have been used, whole cell tumor lysates or irra-
diated, apoptotic tumor cell bodies have been applied, and
TAA-encodingplasmidsorTAA/wholetumorcellRNAwere
to try out. Besides the choice of the antigen the strategy of
antigen delivery must be optimized. The above stated tumor
antigens could be used as vaccines alone or together with
additives like GM-CSF, IFN-α, or IL-12. Instead of using the
antigens as direct vaccines, they can also be brought into the
body by dendritic cells. This review will focus on the use of
RNA either alone or in combination with dendritic cells as
a cancer vaccine. An overview over both methods is given in
Figure 1.
4.DendriticCells
Inthedevelopmentofvaccinesagainstcancer,manyresearch
groups focus on the usage of dendritic cells (DCs). DCs are,
besides B cells and macrophages, antigen presenting cells
(APCs)andareseenasthemostpotentpopulationexecuting
this function.
In their immature state, DCs mostly reside in tissues and
in part travel through the blood and lymph streams. They
express major histocompatibility complex (MHC) class II
molecules, but only few costimulatory molecules like CD80
(B7.1) or CD86 (B7.2). While migrating through the body’s
periphery, DCs eventually encounter antigens. The cells
incorporate these antigens through a variety of processes,
namely, receptor-mediated endocytosis, phagocytosis, or
macropinocytosis. After antigen ingestion, DCs migrate
towards aﬀerent lymphoid organs and diﬀerentiate into
mature cells. During the maturation process DCs undergo
several phenotypic and functional changes. They upregulate
the expression of MHC class I and II molecules [35], the
costimulatory molecules CD80, CD86 [36], and CD40 [37],
as well as the adhesion molecules CD54 (ICAM-1), CD102
(ICAM-2),CD11a(LFA-1),CD58(LFA-3),andCD209(DC-
SIGN) [38–40]. As another prominent change, mature DCs
increase the secretion of cytokines (IL-6, IL-12, IL-23, TNF-
α) and chemokines like CCL18 (DC-CK-1), which draws
na¨ ıve T cells to the location.Journal of Biomedicine and Biotechnology 3
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Figure 1: Overview over RNA-vaccination schemes using DCs (A) or pure/stabilized RNA.
Through their matching adhesion molecules, DCs and
residing T cells interact with each other, forming immuno-
logical synapses. As a consequence, DCs present the pro-
cessed antigens to T cells, these get activated, and antigen-
speciﬁc responses are generated.
Depending on the nature of the antigen, either MHC
class I or class II molecules are involved in their presentation.
Like almost all cells of the body, DCs have the ability to
present antigens via MHC class I molecules. This route
is taken when antigens are of endogenous origin. After
proteasomal degradation in the cytosol, generated peptides
are transported into the ER, loaded onto MHC class I
molecules, and brought to the cell’s surface. There, the MHC
c l a s sIm o l e c u l e si n t e r a c tw i t hTc e l lr e c e p t o r sf r o mC D 8
positive cytotoxic T lymphocytes (CTLs).
DCs can present exogenous antigens over MHC class II
molecules. After incorporation, the antigens are degraded in
endosomal-lysosomal compartments by cathepsins. Gener-
ated peptides are loaded onto MHC class II molecules, which
interact with CD4 positive T cells.
Besides following the “classical” pathways of antigen
processing and presentation, DCs are able to present exoge-
nous antigens through MHC class I molecules. Engulfed
antigens are transferred from lysosomal compartments into
the cytosol and then follow the MHC class I pathway of
processing and presentation. Through this so-called cross-
priming, eﬀective CTL responses can be generated [41–43].
5. In Vitro Generationof Dendritic Cells
The employment of DCs in vaccination strategies requires
large amounts of this cell type. Until now, several protocols
have been established for the generation of high quantities in
vitro. DCs can be generated from CD34 positive precursors
from bone marrow or blood, when the cells are incubated
with cytokine cocktails containing granulocyte-macrophage
colony stimulating factor (GM-CSF), IL-4, or TNF-α [44–
46]. A diﬀerent approach uses CD14 positive monocytes
from blood and the cytokines GM-CSF and IL-4 or CD40
ligand to generate myeloid DCs [47–49]. These cells are
immature and express few costimulatory molecules on their
surface but can be matured with diﬀerent inﬂammatory
stimuli like Toll-like receptor ligands, TNF-α, or a mixture of
compounds containing PGE2,T N F - α,I L - 1 β, and IL-6 [50].
6. Usage of RNA
RNAs, ribonucleic acids, are single-stranded polymers in
their primary structure, containing the four nucleotides
adenosine, guanosine, cytidine, and uridine monophos-
phate. These are linked through the 3  and 5  phosphate
residues of the ribose sugars. In immunotherapy, messenger
RNA (mRNA) is used, which contains the genetic informa-
tion for proteins. The structure of processed and spliced
mRNA has ﬁve structural features: A Cap structure, which
is a 7-methylguanosine triphosphate, the 5 -untranslated
region(UTR),theopenreadingframe(ORF)beginningwith
the start codon at the 5  end and ending with the stop codon
at the 3  end, the 3 -UTR, and a poly A-tail at the 3  end
containing 100–250 residues.
In the ﬁrst vaccination approaches, mRNA was extracted
fromautologoustumortissuesfrompatients.Thisprocedure
had the disadvantage that suﬃcient amounts of tumor cells
had to be available. Nowadays it is possible to prepare high
amounts of RNA in vitro. From few tumor cells one can
extract RNA and generate complete tumor cDNA libraries
to obtain the necessary amounts of RNA encoding multiple
patient speciﬁc TAAs in the needed quality [51, 52]. Besides
the easy access to large quantities, the application of mRNA
provides several advantages as a vaccine. RNA molecules are
considered to be safe vaccines, as they are easily degraded.
They are cleared quickly out of the organism and cannot,4 Journal of Biomedicine and Biotechnology
as opposed to plasmid DNA, integrate into the genome
and inﬂuence the cell’s gene expression in an uncontrollable
manner [53]. Due to the stated facts, it is also unlikely
that RNA vaccination causes severe side eﬀects like the
generation of autoimmune disease or anti-DNA antibodies.
As a plus, the application of mRNA is, unlike peptide-based
vaccinations, not MHC-restricted. An immune response
against a broad variety of antigens can be generated and
CD8 positive CTLs as well as CD4 positive T helper cells can
get induced. A polyclonal immune response makes tumor
escape less likely. Although the expression of genes cannot be
regulated when RNA is used, this is eventually not necessary
due to the molecule’s instability. Unlike DNA, which has to
be transfected into the nucleus, the transfection with RNA
requires only insertion into the cell’s cytoplasm, which is
easier to achieve. All these issues speak for the utilization of
RNA-based vaccines.
7.RNA-Pulsed DCsasVaccines
One basic approach in RNA vaccination is the use of in vitro
generated DCs as tumor antigen-presenting cells. Generated
DCs can be transfected with RNA encoding single or
multiple TAAs or whole tumor cell RNA. After transfection,
thegeneticinformationintroducedintotheDCsistranslated
into protein. These proteins underlie intracellular degrada-
tion processes and the generated peptides are presented on
MHC class I and class II molecules.
Several in vitro experiments showed that DCs pulsed
with whole tumor RNA or RNA encoding speciﬁc TAAs
induce the generation of speciﬁc CTLs. This procedure was
ﬁrst described by the group of Gilboa and formed the basis
for ongoing experiments [54]. Milazzo et al. electroporated
monocyte-derived DCs with whole RNA from LP-1 and
U266 cell lines and induced speciﬁc CTLs that lysed LP-
1 and U266 myeloma cells [55]. In diﬀerent experiments,
scientists used RNA from tumor-bearing patients instead of
cell lines to generate CTL responses. Heiser et al. transfected
DCs with RNA isolated from renal tumor cells [56]. The
group showed the generation of polyclonal CTL responses
and subsequent lysis of primary and metastatic tumor
cells. Apparently, the polyclonal T cell activities were more
potent than the CTL responses generated against a single
antigen. However, in other settings the potency of immune
responses induced by single TAAs was investigated. Nair et
al. transfected DCs with CEA mRNA and stimulated speciﬁc
CTL responses in vitro [24]. Grunebach et al. analyzed
the inﬂuence of cotransfection of two diﬀerent TAAs and
electroporated DCs with Her-2/neu and 4-1BBL RNA. They
found that costimulatory molecules were upregulated and
immune responses were increased in comparison to single
TAA transfection. Both CD8 and CD4 T cell responses were
induced [57].
The transfection of DCs with RNA already leads to the
initiation of the maturation process. It is still questioned
if these stimuli are enough or if additional signals lead to
more capable cells. Several additional maturation stimuli
have been analyzed on the eﬀect on DC phenotype and
eﬀectiveness on T cell proliferation and thus the generation
of speciﬁc immune responses. Onaitis et al. transfected DCs
with mRNA encoding Mart-1 and partly matured the cells
with CD40 ligand [58]. An enhanced T-cell proliferation was
found in the preparations with CD40L stimuli, which was
due to the increased IL-12 secretion by the treated DCs.
The same group discovered that the sequential stimulation
with a cytokine cocktail (TNF-α,I L - 1 β,I L - 6 ,a n dP G E 2)
followed by incubation with CD40L enhances the generation
of Mart-1-speciﬁc T cells, an eﬀect again mediated by
increased IL-12 production [59]. They also described the
eﬀective maturation of DCs by diverse Toll-like receptor
ligands [60, 61]. In mouse experiments the generation and
further enhancement of T cell responses has been analyzed.
Boczkowski et al. induced OVA-speciﬁc CTLs and protection
from OVA-expressing tumors in mice [54]. Naka et al.
c o t r a n s f e c t e dm o u s eD C sw i t ht u m o rR N Aa sw e l la sG M -
CSF RNA and used the cells as a vaccine [62]. The animals
had already received immunotherapeutic treatment in a
previousexperimentandthere-growingofthetumorshould
be inhibited. The co-transfected DCs successfully induced
augmented CTL responses and suppressed tumor growth.
Kim et al. investigated whether it is possible to enhance
immune responses against the antigen CEA when the TAA
is modiﬁed. The group generated a fusion gene containing
a truncated CEA (CEA) devoid of its signal sequences,
calreticulin (CRT), and the HIV TAT protein transduction
domain (TAT-PTD) and pulsed DCs with the according
RNA. The vaccine enhanced CEA-speciﬁc CD4 and CD8
responsesandinhibitedtumorgrowthandledtoaprolonged
survival of treated mice [63].
The promising results from in vitro experiments and
studies in mice led to several human trials where patients
with diﬀerent malignancies were vaccinated with RNA
transfected DCs (see Table 1).
Heiser et al. conducted a study on metastatic prostate
cancer [64]. Sixteen patients were initially enrolled in the
phase I trial and 13 followed the immunization schedule
with PSA RNA-transfected DCs. The patients received 3
intravenous vaccination cycles with escalating doses of DCs,
namely 1 × 107 cells (low dose), 3 × 107 cells (medium
dose), and 5 × 107 cells (high dose), together with, 1 ×
107 DCs intradermally administered at weeks 2, 4, and
6 .T h ee v a l u a t i o no fs p e c i ﬁ cTc e l lr e s p o n s e sw a sc a r r i e d
out via ELISPOT and [51Cr]-chromium-release assays. All
nine patients that were analyzed showed PSA-speciﬁc CTL
responses. Additionally, a decrease in the log slope PSA
was detected in six of seven patients and three patients
transiently showed clearance of circulating tumor cells. No
severe adverse eﬀects were observed after the vaccinations,
stating the safety of this type of vaccine.
CEA is an important tumor marker expressed in col-
orectal, pancreatic, and gastric carcinomas as well as in the
majority of breast and nonsmall cell lung cancers. The TAA
has been object of recent phase I/II studies to evaluate its use
in vaccination therapy. Immunizations with CEA mRNA-
transfected DCs were administered to three patients with
resected pancreatic adenocarcinoma [65]. The injections
were given monthly for a time period of six months and the
treated patients showed no recurrence of disease in the moreJournal of Biomedicine and Biotechnology 5
Table 1: Recent clinical trials using RNA-transfected DCs.
Cancer type RNA source/target Vaccination schedule Number of
study subjects
Immunological
response
Clinical
response Reference
Colorectal
cancer
Total autologous
tumor
106 DCs pulsed with 25μgR N Aa n dK L H
intravenously 4 times on monthly
intervals.
15 NA NA [73]
Adenocar-
cinoma
(lung)
Total autologous
tumor
3 × 107 DCs transfected with 300μgR N A
intravenously, followed by 106 DCs
t r a n s f e c t e dw i t h1 0μg RNA intradermally
4 times on monthly intervals.
11 / 1 N A [ 93]
Pancreatic
cancer CEA
107 DCs transfected with 20μgR N A
intradermally 6 times on monthly
intervals.
3N A N A [ 65]
Prostate PSA
107–5 × 107 DCs transfected with 1.5μg
RNA/106 DCs intravenously, 3 times
biweekly with escalating dose and 107
DCs intradermally.
16 9/9 NA [64]
CEA-
expressing
cancers
CEA
107-108 DCs transfected with 2μg
RNA/106 DCs intravenously and 0–106
trasnfected DCs intradermally 4 times
biweekly.
42 NA NA [94]
RCC Total autologous
tumor
107–5 × 107 DCs transfected with 50μg
RNA/107 DCs intravenously, 3 times
biweekly with escalating dose and 107
DCs intradermally.
15 6/7 NA [72]
Brain cancer Total autologous
tumor
0.5–5 × 107 DCs/m2 transfected with 5μg
RNA/ 106 DCs intravenously and 0.5 ×
107 DCs/m2 intradermally, 3 times
biweekly with escalating dose, 3 times at
3-month intervals.
9N A 2 / 7 S D [ 95]
Neuroblas-
toma
Total autologous
tumor
0.5–5 × 107 DCs/m2 transfected with 5μg
RNA/106 DCs intravenously and 0.5 ×
107 DCs/m2 intradermally, 3 times
biweekly with excalating dose, 3 times at
3-month intervals.
11 NA 1/7 SD [96]
RCC, OVA
Total tumor from
clear cell carcinoma
tissue
Arm 1: 107 D C se l e c t r o p o r a t e dw i t h5μg
RNA/106 DCs intradermally, 3 times
biweekly, 18μg/kg DAB389 IL-2 prior to
vaccination.
Arm 2: 107 D C se l e c t r o p o r a t e dw i t h5μg
RNA/106 DCs intradermally, 3 times
biweekly.
11
Arm 1: 7
Arm 2: 4
10/11
Arm 1: 7/7
Arm 2: 3/4
NA [83]
Prostate hTERT, LAMP
hTERT
Arm 1: 107 D C se l e c t r o p o r a t e dw i t h1μg
hTERT RNA/106 DCs intradermally, 3 (6
patients) or 6 (5 patients) times weekly.
Arm 2: 107 D C se l e c t r o p o r a t e dw i t h1μg
LAMP hTERT RNA/106 DCs
intradermally, 3 (6 patients) or 6 (3
patients) times weekly.
20
Arm 1: 11
Arm 2: 9
17/18 NA [97]
Prostate
Total tumor from
prostate cancer cell
lines DU145,
LNCaP, PC-3
2 × 107 electroporated DCs intranodally
or intradermally, at least 4 times weekly. 19 12/19 11/19 SD [98]
Melanoma Total autologous
tumor
Arm 1: 2 × 107 electroporated DCs
intradermally 4 times weekly.
Arm 2: 2 × 107 electroporated DCs
intranodally 4 times weekly.
22
Arm 1: 10
Arm 2: 12
9/19 2/20 [68]
Melanoma Mage-A3, Mage-C2,
tyrosinase, gp100
1.25 × 107 electroporated TriMix DCs
intradermally, 4 times biweekly. 32 / 2 N A [ 71]
NA: Not applicable; SD: Stable disease.6 Journal of Biomedicine and Biotechnology
than 2.5 years. In a parallel study, DCs loaded with CEA
mRNA were administered to patients with CEA-expressing
tumors (phase I study) or with resected hepatic metastases
of colon cancer (phase II study) in escalating doses. While 24
patients were enrolled in the phase I trial, only one showed
a complete response, 2 patients exhibited minor responses,
and 3 patients showed a stable disease. The clinical response
in the phase II study was similarly poor. Nine of 13 patients
showed recurrence of disease.
These examples can stand for several clinical phase I/II
studies that have been performed and that show an analog
outcome. The induction of speciﬁc CTLs after vaccination
works well and strong immune responses can be observed in
vitro, but only little eﬀects are seen when looking at the clini-
cal responses. The majority of the treated patients showed no
beneﬁt from the vaccinations; that is, no tumor regression
or protection from recurring disease was noticeable. The
diﬀerence between in vitro analyses and in vivo outcome
could be due to the large tumor burden of the patients, the
occurrence of regulatory T cells or myeloid suppressor cells,
and induction of tolerance or consequences of medical pre-
treatment.
Still, scientists have thought of multiple ways to make
vaccinations with RNA-transfected DCs more eﬃcient.
There are many variables when it comes to the generation of
DC vaccines and many issues must be considered. One item
is the question of the vaccine dose. This entails in detail the
numberofadministeredDCsandifanescalatingdoseshould
be used or not, the number of injections, and the injection
interval. Another point is the route of administration.
Diﬀerent injection sites are possible forthe administration of
DC-based vaccines. The cells can be injected intradermally,
subcutaneously,intravenously,intranodally,anddirectlyinto
the tumor. As DCs migrate to lymphatic tissues after their
administration, it is subject of investigation which route
leads to the most eﬀective immune responses. Intranodal or
intradermal close to lymph nodes seemed to be promising,
more than i.v. in one trial using peptide-pulsed DCs [66, 67].
When comparing intradermal versus intranodal injections
of RNA-transfected DCs, the intranodal injection showed
no signs of superiority [68, 69]. The diﬀerent results might
be due to the complexity of accurate DC vaccination.
Intranodal injections lead to the accumulation of DCs in
the lymph nodes. However, the accurate administration is
more diﬃcult than i.d. or i.v. injections and vaccines can be
accidently delivered into perinodal fat [70]. As the route of
administration aﬀects the migration of DCs signiﬁcantly, the
optimal way has to be found for the treatment of diﬀerent
malignancies.
Another important issue is the antigen that has to be
transfected into DCs. It is possible to pulse the cells with
one or several TAAs or whole cell tumor RNA. Theoretically
the application of the latter allows the generation of immune
responses against a broad variety of antigens. It is still a
matter of investigation if this approach is more eﬀective than
the use of several speciﬁc TAAs. If enough tumor material
i sa v a i l a b l e ,w h o l eR N Ac a nb ee x t r a c t e df r o mt u m o rt i s s u e s
andusedforvaccinepreparation.Ifthisisnotthecase,cDNA
libraries can be created followed by cloning, ampliﬁcation in
E. coli, and ﬁnally in vitro transcription of RNA [51]. What
actually is an advantage when it comes to the number of
patients that can be treated following this approach also has
a negative impact on the composition of the RNA mixtures,
as in vitro transcription leads to the occurrence of shorter
fragments [51].
The actual delivery of RNA into dendritic cells can
be achieved in diﬀerent ways. The transfection can be
performed using liposomes and cationic lipids. These bind
automatically to RNA due to their charge and form com-
plexes that interact with the target cells. The cationic lipids
DOTAP [54]o rD M R I E[ 24] have been used for success-
ful DC transfection. One disadvantage of lipid-mediated
transfection is the toxicity of the mixture. Therefore, the
ratio between RNA and lipids and the used concentration
must be optimized. Another successful approach is the
electroporation [71] of dendritic cells in the presence of
RNA. The application of an electrical pulse causes the cells to
take up enough RNA for antigen presentation. Finally, RNA
can be introduced into DCs by passive transfection [72].
Immature DCs absorb particles and media as part of their
function without external stimuli. This fact suggests that the
cells will take up RNA present in the surroundings of the
DCs. The passive RNA pulsing without the use of additives
was shown to work successfully as well.
As in vitro experiments showed, the add-on of further
stimuli can lead to enhanced immune responses as well.
Rains et al. conducted a study on patients suﬀering from col-
orectal cancer [73]. They pulsed DCs with tumor RNA and
keyhole limpet hemocyanin (KLH) for vaccine preparation.
KLH is an immunogenic protein supposed to enhance the
eﬃciency of the DC vaccination. In the study, eleven of 13
patients developed responses againstKLHand sevenpatients
showed a decrease in CEA levels.
A complex in vivo study was performed by Bonehill et
al. in which the group generated so-called TriMix DCs [71].
Dendritic cells were electroporated with mRNA encoding
CD40L, CD70, anda constitutively active TLR4 asenhancing
elements. The cells were additionally electroporated with
either Mage-A3, Mage-C2, tyrosinase, or gp100 mRNA.
Two melanoma patients received four biweekly intradermal
injections at four diﬀerent sites of 1.25 × 107 TriMix DCs
per antigen. While antigen-speciﬁc CD8 T cell responses
were detected in both patients after ﬁnished treatment,
no data about clinical responses were published on this
trial.
The discussed approaches have analyzed several possibil-
ities in vaccine preparation and administration. Even more
and diﬀe r e n ts e t t i n g sh a v et ob ei n v e s t i g a t e di nt h ef u t u r et o
ﬁnd the optimized conditions for this type of treatment.
8.RNA Vaccines
Besides using in vitro preparations of dendritic cells for
antigen presentation, another approach directly uses RNA
vaccines. It has been shown that RNA can be transfected
into DCs without the help of additives like liposomes
or electroporation. Therefore, an obvious approach is the
vaccination with naked RNA.Journal of Biomedicine and Biotechnology 7
To deliver mRNA into patients in an eﬀective manner,
several issues have already been considered and tried out.
RNA molecules themselves are thought to be relatively
instable and easily degradable. For this reason there used to
be much doubt, if the injection of the naked RNA molecules
makes sense. However, Wolﬀ et al. injected naked RNA into
the skeletal muscle of mice and showed that the encoded
protein was expressed in situ [74]. Furthermore, it could be
shown that even the application of unprotected RNA could
inducespeciﬁcCTLresponsesinpatients.Still,somethought
has been given to stabilize RNA molecules and make delivery
more eﬃcient.
One possibility for RNA administration is to code the
nucleic acid on gold particles and subsequent “gene-gun
delivery” [75]. The particles are used as shuttles to carry the
RNA molecules through skin. After incorporation by DCs,
the encoded proteins are expressed and presented to T cells.
Another approach, which has been analyzed, is the pack-
aging of RNA into liposomes. Liposomes contain cationic
lipids which interact electrostatically with negatively charged
nucleic acid molecules and form stable complexes [76].
Liposomes not only stabilize RNA, but already activate
immune cells by themselves, and thus are supporting as
adjuvants [77, 78].
Another way to stabilize RNA is its condensation to pro-
tamine [52], an arginine-rich protein essential for DNA con-
densationinspermatogenesis.Protamineformsspontaneous
complexes with RNA in vitro, which are immunostimulating
for several hours. Besides protection of RNA, protamine
functions as a danger signal and activates in a MyD88-
dependentway human DCs aswellasmonocytes, B cells,NK
cells, and granulocytes.
Other ways to modify RNA to make it more resistant
against degradation and more eﬃcient for translation are the
elongation of the poly-A tail at the 3 -end of the molecule
and the manipulation of the Cap structure at the 5 -end.
If the original 7-methylguanosine triphosphate is replaced
by an Antireverse Cap Analog (ARCA), the eﬃciency of
transcription is strongly enhanced.
To provide the immune system with even more potent
signals, RNA has been modiﬁed to generate sequences with
a phosphorothioate backbone [79]. Phosphothioate RNA
serves as a danger signal and activates mouse DCs through
MyD88 [79].
As discussed in connection with RNA-transfected DCs,
the optimal injection site for immunostimulatory RNA has
been a matter of research. RNA alone can be injected using
the following routes: subcutaneous, intradermal, intramus-
cular, and intranodal. Injections close or into the lymph
nodes seem to be preferable, as they induce the generation
of strong immune responses.
By now, several in vivo studies have been carried out
to analyze the use of RNA in tumor vaccines. Carralot
et al. injected β-globin UTR-stabilized RNA encoding β-
galactosidase intradermally into BALB/c mice [80]. The
model antigen was translated in vivo, which was shown
by speciﬁc staining. Interestingly, IgG1 antibodies against
β-galactosidase were found after the vaccination, which
are characteristic for a TH2 immune response. This result
seemed to be contrary to other studies using DNA vaccines,
where the generation of IgG2 antibodies was induced. The
latteristypicalforaTH1response,whichispreferredinanti-
tumorimmunotherapy.Thestudyshowedtheimportanceof
the type of antigen used for the vaccine in means of DNA
or RNA, as it is obviously more important than the delivery
route.
Until now, only few phase I/II trials have been carried
out using RNA as a vaccine (see Table 2). Schmidt et
al. vaccinated 30 RCC patients with naked tumor RNA
coding for the TAAs MUC1, CEA, Her-2/neu, telomerase,
surviving, and MAGE-1. The patients received intradermal
injections on days 1, 14, 28, and 42 (group A), while
group B received vaccinations on days 0–3, 7–10, 28,
and 42 following monthly injections. The generation of
antigen-speciﬁc immune responses was analyzed in vitro by
ELISPOTassays.BothCD4+andCD8+Tcellresponseswere
induced for diverse antigens. Seven patients additionally
showedaclinicalresponse.Nosevereadverseeﬀectsoccurred
demonstrating the safety of the approach [81].
Weide et al. carried out two distinct trials on metastatic
melanoma [5, 82]. In the ﬁrst phase I/II study patients
with stages III and IV received intradermal injections of
in vitro transcribed naked whole tumor RNA. The patients
were vaccinated with four times every two weeks followed
by monthly injections for six months. 24 hours after each
vaccination, the patients were injected subcutaneously with
GM-CSF as an adjuvant. After treatment, melanoma cell
line-speciﬁc antibodies were detected in four of 15 patients
and speciﬁc T cell responses were probably induced in
ﬁve patients. Looking at the clinical response, two patients
showed a mixed response and ﬁve patients a favourable
course of disease, but no clinical regression was seen. The
vaccine itself proved to be safe, as only mild and reversible
side eﬀects occurred.
In the second phase I/II study, not whole tumor RNA
was used for vaccination, but six deﬁned RNAs encoding
the TAAs Melan-A, tyrosinase, gp100, Mage-A1, Mage-A3,
and survivin. The metastatic melanoma patients received
escalating doses of RNA, a higher number of injections in
comparison to the ﬁrst study, and instead of using naked
RNA the nucleic acids were stabilized with protamine. Addi-
tionally, KLH was used as a helper antigen and added to the
vaccine of half of the patients. Again, GM-CSF was injected
24 hours after vaccination. The intense vaccination schedule
contained 12 vaccinations administered in 19 weeks. The
analysis of induced T cell responses showed no consistency
between diﬀerent patients. Out of four patients, one showed
an increase in CD8 and CD4 T cells, a second patient showed
ﬁrst an increase for both T cell populations, but then a
decline and no diﬀerence was seen in two other patients.
The few number of patients and the individual diﬀerences
make the outcome uncertain. In addition, the numbers of
immunosuppressive cells were monitored. While the KLH+
arm exhibited a decrease of regulatory T cells (Tregs), the
KLH-arm showed a decrease in myeloid suppressor cells. A
clinical response was seen in one of seven stage IV patients.
Again,thestudyresultsshowedonlyfewachievementsbythe
administered immunotherapy. The group pointed in their8 Journal of Biomedicine and Biotechnology
Table 2: Recent clinical trials using RNA.
Cancer type RNA Vaccination schedule Number of
study subjects
Immunological
response Clinical response Reference
Melanoma Total tumor
200μg naked RNA intradermally,
biweekly for 8 weeks, followed by
monthly injections for 6 months.
150μg GM-CSF subcutaneously 24 h
after RNA injection.
15 NA 2/13 MR
3/13 NED [5]
Melanoma
Melan-A,
tyrosinase,
gp100,
Mage-A1,
Mage-A3,
survivin
Arm 1: 3.2–80μg RNA per antigen +
128μg protamine intradermally on
days 1, 3, 5, weeks 2, 3, 4, 5, 6, 7, 11, 15,
19. 200μg GM-CSF subcutaneously 24
h after RNA injection.
Arm 2: 3.2–80μg RNA per antigen +
128μg protamine + 4mg KLH
intradermally on days 1, 3, 5, weeks 2,
3, 4, 5, 6, 7, 11, 15, 19. 200μg GM-CSF
subcutaneously 24h after RNA
injection.
21
Arm 1: 11
Arm 2: 10
Vaccine directed T
cells: 2/4
Arm 1: 1/11 CR
4/11 NED
Arm 2: 1/10 NED
[99]
RCC
MUC1, CEA,
Her-2/neu,
telomerase,
surviving,
MAGE-1
Arm 1: 20μg naked RNA per antigen
intradermally on days 0, 14, 28, 42,
followed by monthly injections.
100μg/m2 GM-CSF subcutaneously 24
h after RNA injection.
Arm 2: 50μg naked RNA per antigen
intradermally on days 0–3, 7–10, 28,
42, followed by monthly injections.
250μg/m2 GM-CSF subcutaneously
24h after RNA injection.
30,
Arm 1: 14
Arm 2: 16
CD4+ ELISpot: 3/7
CD8+ ELISpot: 8/9
CD8+ Cr-Release
Assay: 7/11
Arm 1:
1/14 PR
6/14 SD
Arm 2:
9/16 SD
[81]
CR: Complete response; MR: Mixed response; NA: Not applicable; NED: No evidence of disease; PR: Partial response; SD: Stable disease.
report to the possible role of immunosuppressive cells for
the treatment. This issue is eventually one reason why there
is a huge discrepancy in clinical trials when comparing the
generation of speciﬁc antitumor immune responses in vitro
and the clinical response of patients.
9.OptimizationofImmunotherapy
CD4+CD25+ regulatory T cells are important for self-
tolerance and have suppressor functions in the immune
system. They control immune responses and reduce the risk
of T cell responses being harmful to the body. Elevated
numbers of Tregs are linked to a reduced survival in tumor
patients. Thus, the depletion of Tregs could prolong the life
of patients and strengthen the induced immune responses.
Dannull et al. vaccinated RCC patients with RNA-
transfected DCs and additionally reduced the number of
regulatory T cells [83]. For the depletion of Tregs they used
the recombinant IL-2 diphtheria toxin conjugate DAB389IL-
2 (ONTAK), which selectively eliminates CD25-positive reg-
ulatory T cells. A signiﬁcant increase of tumor-speciﬁc CD8
andCD4Tcellresponseswasobservedforthecombinational
therapy opposed to injections with DC vaccines alone.
Another approach to eliminate inhibitory immune
mechanismsisthetargetingofCTLA-4.CytotoxicTlympho-
cyte antigen (CTLA)-4 is homologous to the costimulatory
B7moleculesandanegativeregulatorforTcellproliferation.
Like B7, CTLA-4 binds to CD28. However, the aﬃnity of
CTLA-4 to CD28 is higher in comparison to B7 and the
interaction leads to the inhibition of T cell proliferation.
After T cell activation, CTLA-4 expression is increased,
making the interaction with CD28 more and more likely and
giving a negative feedback mechanism. The importance of
CTLA-4 is pointed out by certain CTLA-4 polymorphisms
which lead to autoimmune diseases [84]. Another evidence
for the importance in controlling T cell responses is found
in mice with lympho-proliferatory diseases not expressing
CTLA-4 [85, 86].
The inhibition of CTLA-4 could lead to the gener-
ation of enhanced T cell responses. Tremelimumab and
Ipilimumab are both humanized anti-CTLA-4 inhibitory
antibodies. Their application in melanoma trials led to
better clinical responses in treated patients [87]. Along
with these promising results went severe side eﬀects like
diarrhea, panhypopituitarism, and autoimmune thyroiditis.
These immune-related adverse events (IRAEs) probably go
along with positive clinical responses. Further investigation
should stress on the safety issues of CTLA-4 inhibition, as
long-time treatment could lead to autoimmune phenomena.
In ongoing studies the utilization of several immune-
modulatory mechanisms together with CTLA-4 inhibition is
investigated [88].
Besides the inhibition of undesirable immune eﬀects, it
is possible to further stimulate mechanisms that activate the
immune system. Compounds with enhancing qualities are,
for instance, nonmethylated cytosine-guanine dinucleotidesJournal of Biomedicine and Biotechnology 9
(CpGs) [89, 90]. These synthetic oligodeoxynucleotides are
homologues to bacterial or viral DNA and stimulate TLR9.
TLR9 is a pattern-recognition receptor belonging to the
TLR family. It is located in the endosomal compartments of
dendritic cells and macrophages and activates APCs at the
occurrence of PAMPS. The synthetic oligodeoxynucleotide
PF-3512676, for instance, enhances the induced immune
response and prevents induction of immune tolerance [91].
Another possibility to enhance antitumor eﬀects is the
combination of RNA-vaccination with the administration
of tyrosine kinase inhibitors (TKIs). The TKIs sorafenib
and sunitinib inhibit intracellular signaling pathways leading
to proliferation and angiogenesis. Sorafenib is applied in
the therapy of renal cell carcinoma (RCC) and hepato-
cellular carcinoma (HCC). Sunitinib is administered in
RCC and gastrointestinal tumor (GIST) treatment. Recent
mouseexperimentsshowedthatpretreatmentwithsorafenib
reduced the induction of antigen-speciﬁc T cells, while
sunitinib had no such eﬀect [92]. In human monocyte-
derived DCs, sunitinib had no inﬂuence on DC phenotype
and T cell proliferation, but sorafenib inhibited maturation
processes in DCs and the stimulation of T cells. These
ﬁndings indicate that sunitinib might be a good choice for
combinational therapy with RNA vaccinations.
10. Summary
In the last 20 years many research groups have focused on
the development of immunotherapies to ﬁght malignant
diseases. The main idea behind this approach is the
utilization of apparent diﬀerences between the tumor and
the normal healthy tissue it originated from. An important
discovery supporting ongoing experiments was the ﬁnding
of tumor-associated antigens, which demonstrate the
diﬀerence of altered tissues on the molecular level. TAAs
have been the starting point for several in vitro experiments
and in vivo studies to generate speciﬁc immune responses
against tumor cells.
One feasible and apparently safe approach for vac-
cination is the usage of mRNA encoding TAAs or the
use of whole tumor RNA altogether. RNA can be used
to transfect dendritic cells, which present TAAs, in their
function as antigen-presenting cells, to T cells and generate
a speciﬁc immune response. In more recent studies, the use
of naked RNA plus possible enhancers has been analyzed
in vaccination trials as well. For both methods exist a
broad variety of variables that can be modiﬁed at vaccine
administration. Due to this diversity, ongoing trials basically
never follow the same approach twice, but instead single
items are systematically changed for each new study. Many
more trials might be needed before the best vaccination
schemes will be found. However, the use of RNA vaccination
might be the key for the cure of diverse types of malignant
diseases.
Until now, in vivo trials have in common that the
generation of speciﬁc T cells is induced after the vaccination
of patients, but clinical outcomes are observed rarely. Often,
the progression or recurrence of disease is observed instead
of tumor clearance. Thus, latest studies deal with the
enhancement of the eﬀectiveness of vaccines. One possibility
is the combination of RNA vaccination and the further
stimulation of the immune system by cytokines and TLR
ligands together with the inhibition of cell populations
that suppress immune responses. When the most eﬀective
vaccination mechanisms will be found, patients will receive
a speciﬁc treatment against their individual disease. The
stimulation of the patient’s immune system will lead to
the generation and maintenance of an eﬀective immune
response. Hopefully, the vaccination with RNA will enable
the control of malignant disease.
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